Low dosage of apatinib monotherapy as rescue treatment in advanced lung squamous cell carcinoma

  • Da-xiong Zeng
  • Wei Lei
  • Chang-guo Wang
  • Jian-an Huang
  • Jun-hong JiangEmail author
Original Article



Platinum-based doublet chemotherapy and radiotherapy are the standard treatment option in advanced squamous cell carcinoma patients. However, few agents could be selected for subsequent post-second-line treatment. As a small molecule inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase, apatinib had been proved in advanced gastric cancer. Here, we showed its efficacy and safety in lung squamous cell carcinoma.


In this retrospective study, 13 advanced lung squamous cell carcinoma patients were enrolled. They received doublet chemotherapy or docetaxel as the first-line treatment. After disease progressed, all patients were administrated apatinib monotherapy (250–425 mg/day) for second-line or fourth-line therapy.


After apatinib monotherapy, two patients achieved partial response, four patients achieved stable disease, and seven patients achieved progression disease. The medium PFS was 3.1 months. The median OS had not yet been reached. The objective remission rate was 15.4% (2/13). The total disease control rate was 46.2% (6/13). The main advert effects were vomiting and hypertension.


Apatinib might be an option as rescue treatment in advanced lung squamous cell carcinoma.


Squamous cell carcinoma VEGFR-2 Apatinib 



This study was supported by Jiangsu Province Special Program of Medical Science (BE2016672), Program of Key Talents of Medical Science in Jiangsu Province (QNRC2016745), Clinical Key Speciality Project of China, Clinical Medicine Center of Suzhou (No. SZZX201502), Suzhou Key Laboratory for Respiratory Medicine (No. SZS201617).

Compliance with ethical standards

Conflict of interest

No conflict of interest.


  1. 1.
    Gridelli C, de Marinis F, Cappuzzo F et al (2014) Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer 15:173–181CrossRefGoogle Scholar
  2. 2.
    Janku F, Garrido-Laguna I, Petruzelka LB et al (2011) Novel therapeutic targets in non-small cell lung cancer. J Thorac Oncol 6:1601–1612CrossRefGoogle Scholar
  3. 3.
    Herbst RS, Onn A, Sandler A (2005) Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 23:3243–3256CrossRefGoogle Scholar
  4. 4.
    Goel HL, Mercurio AM (2013) VEGF targets the tumour cell. Nat Rev Cancer 13:871–882CrossRefGoogle Scholar
  5. 5.
    Sandler A, Gray R, Perry MC et al (2006) Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550CrossRefGoogle Scholar
  6. 6.
    Garon EB, Ciuleanu TE, Arrieta O et al (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384:665–673CrossRefGoogle Scholar
  7. 7.
    de Gramont A, Van Cutsem E, Schmoll HJ et al (2012) Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 13:1225–1233CrossRefGoogle Scholar
  8. 8.
    Pujade-Lauraine E, Hilpert F, Weber B et al (2014) Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 32:1302–1308CrossRefGoogle Scholar
  9. 9.
    Hu X, Zhang J, Xu B et al (2014) Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer. Int J Cancer 135:1961–1969CrossRefGoogle Scholar
  10. 10.
    Li J, Qin S, Xu J et al (2013) Apatinib for chemotherapy-refractory advanced metastatic gastriccancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol 31:3219–3225CrossRefGoogle Scholar
  11. 11.
    Ding L, Li QJ, You KY et al (2016) The use of apatinib in treating nonsmall-cell lung cancer: case report and review of literature. Medicine (Baltimore) 95:e3598CrossRefGoogle Scholar
  12. 12.
    Song Z, Yu X, Lou G et al (2017) Salvage treatment with apatinib for advanced non-small-cell lung cancer. Onco Targets Ther 10:1821–1825CrossRefGoogle Scholar
  13. 13.
    Xu J, Liu X, Yang S et al (2018) Clinical response to apatinib monotherapy in advanced non-small cell lung cancer. Asia Pac J Clin Oncol 14:264–269CrossRefGoogle Scholar
  14. 14.
    Zeng DX, Wang CG, Lei W et al (2017) Efficiency of low dosage apatinib in post-first-line treatment of advanced lung adenocarcinoma. Oncotarget 8:66248–66253PubMedPubMedCentralGoogle Scholar
  15. 15.
    Zeng DX, Wang CG, Huang JA et al (2017) Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation. Onco Targets Ther 10:4269–4272CrossRefGoogle Scholar
  16. 16.
    Fang SC, Zhang HT, Zhang YM et al (2017) Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma. Onco Targets Ther 10:447–452CrossRefGoogle Scholar
  17. 17.
    Mi YJ, Liang YJ, Huang HB et al (2010) Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res 70:7981–7991CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Da-xiong Zeng
    • 1
  • Wei Lei
    • 1
  • Chang-guo Wang
    • 1
  • Jian-an Huang
    • 1
  • Jun-hong Jiang
    • 1
    Email author
  1. 1.Department of Respiratory and Critical CareThe First Affiliated Hospital of Soochow UniversitySuzhouPeople’s Republic of China

Personalised recommendations